Cargando…
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851657/ https://www.ncbi.nlm.nih.gov/pubmed/33531462 http://dx.doi.org/10.1038/s41392-021-00481-y |